Expert Review of Vaccines, Год журнала: 2024, Номер unknown
Опубликована: Дек. 6, 2024
Background The dynamic evolution of the virus causing COVID-19 necessitates development adapted vaccines to protect against emerging variants.
Язык: Английский
Science Translational Medicine, Год журнала: 2024, Номер 16(761)
Опубликована: Авг. 21, 2024
Immunological imprinting by ancestral SARS-CoV-2 strains is thought to impede the robust induction of Omicron-specific humoral responses Omicron-based booster vaccines. Here, we analyzed specificity and neutralization activity memory B (B mem ) cells after repeated BA.5 exposure in individuals previously imprinted strain–based mRNA After a second exposure, with spike protein–skewed reactivity were promptly elicited, correlating preexisting antibody titers. Clonal lineage analysis identified BA.5-skewed that had redirected their from strain through somatic hypermutations. Moreover, exhibited accelerated development compared de novo derived naïve repertoires. This demonstrated greater resilience viral point mutation adaptation recent Omicron variants HK.3 JN.1, months suggesting existing elicited older vaccines can redirect toward newly evolving variants.
Язык: Английский
Процитировано
7
Expert Review of Vaccines, Год журнала: 2023, Номер 22(1), С. 650 - 661
Опубликована: Июль 7, 2023
Introduction The Omicron BA.1 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and subsequent sub-lineages exhibit partial escape from neutralizing antibodies elicited by vaccines containing or encoding wild-type spike protein. In response to the emergence sub-lineages, variant-adapted that contain encode for protein components have been developed.Areas covered This review presents currently available clinical immunogenicity safety data on versions BNT162b2 messenger RNA (mRNA) vaccine summarizes expected mechanism action, rationale development, these vaccines. addition, challenges encountered during development regulatory approval are discussed.Expert opinion Omicron-adapted provide a wider breadth potentially more durable protection against antigenically aligned variants when compared with original vaccine. As SARS-CoV-2 continues evolve, further updates may be required. To facilitate this, globally harmonized process transition updated is needed. Next-generation approaches broader future variants.
Язык: Английский
Процитировано
16
Virology, Год журнала: 2025, Номер 606, С. 110509 - 110509
Опубликована: Март 20, 2025
Язык: Английский
Процитировано
0
Life, Год журнала: 2023, Номер 13(10), С. 2094 - 2094
Опубликована: Окт. 21, 2023
Vaccination has been a game-changer in the long battle against COVID-19. However, waning vaccine-induced immunity and immune evasion of emerging variants create challenges. The rapid-fire development bivalent vaccines (BVs), comprising ancestral strains new variant, was authorized to prevent COVID-19, but effectiveness updated remains largely unclear. Electronic databases were searched investigate immunogenicity reactogenicity BVs humans. As March 2023, 20 trials identified. Compared with monovalent vaccination, induced similar. demonstrated approximately 33-50% higher values additional variant strains. An observational cohort study showed clinical BVs. adverse events In conclusion, our systematic review found that had equal without safety concerns. Approximately increased antibody titers observed subjects BV vaccine moderate heterogeneity, especially for BA.1-containing
Язык: Английский
Процитировано
7
iScience, Год журнала: 2024, Номер 27(3), С. 109123 - 109123
Опубликована: Фев. 5, 2024
Conventional neutralizing enzyme-linked immunosorbent assay (ELISA) systems for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mimic the protein-protein interaction between angiotensin-converting enzyme (ACE2) and receptor-binding domain (RBD). However, an easy rapidly adaptative ELISA-based system testing antibodies against upcoming SARS-CoV-2 variants is urgently needed. In this study, we closed gap by developing a tANCHOR-cell-based RBD neutralization that avoids time-consuming protein expression purification followed coating on ELISA plates. This cell-based can be adopted to monitor (NAbs) variants. We show results obtained with strongly correlate commercially available surrogate assays NAbs. Moreover, technique directly measure binding cell-surface-exposed RBDs soluble ACE2. With technique, degree of antibody escape elicited emerging in current vaccination regimens determined reliably.
Язык: Английский
Процитировано
1
Expert Review of Vaccines, Год журнала: 2024, Номер 23(1), С. 730 - 739
Опубликована: Июль 29, 2024
Background Updating vaccines is essential for combatting emerging coronavirus disease 2019 (COVID-19) variants. This study assessed the public health and economic impact of a booster dose an adapted vaccine in United Kingdom (UK).
Язык: Английский
Процитировано
1
Expert Review of Vaccines, Год журнала: 2024, Номер 23(1), С. 750 - 760
Опубликована: Авг. 23, 2024
COVID-19 vaccines adapted to newly emerging circulating variants are necessary better protect the population due evolving nature of SARS-CoV-2 virus.
Язык: Английский
Процитировано
0
Vaccines, Год журнала: 2024, Номер 12(10), С. 1200 - 1200
Опубликована: Окт. 21, 2024
SARS-CoV-2, the causal agent of COVID-19 pandemic, is characterized by rapid evolution, which poses a significant public health challenge. Effective vaccines that provide robust protection, elicit strong immune responses, exhibit favorable safety profiles, and enable cost-effective large-scale production are crucial. The RBD-Fc-based Betuvax-CoV-2 vaccine has previously demonstrated profile induced anti-SARS-CoV-2 humoral response in clinical trials. Due to evolution emergence new SARS-CoV-2 strains, relevance bivalent formulations increased.
Язык: Английский
Процитировано
0
Expert Review of Vaccines, Год журнала: 2024, Номер unknown
Опубликована: Дек. 6, 2024
Background The dynamic evolution of the virus causing COVID-19 necessitates development adapted vaccines to protect against emerging variants.
Язык: Английский
Процитировано
0